BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24680769)

  • 1. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
    Chan JK; Kiet TK; Blansit K; Ramasubbaiah R; Hilton JF; Kapp DS; Matei D
    Gynecol Oncol; 2014 Jun; 133(3):568-74. PubMed ID: 24680769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
    J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
    Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
    Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.
    Steffensen KD; Madsen CV; Andersen RF; Waldstrøm M; Adimi P; Jakobsen A
    Eur J Cancer; 2014 Oct; 50(15):2611-8. PubMed ID: 25087181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
    Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
    Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
    Vincenzi B; Zoccoli A; Schiavon G; Iuliani M; Pantano F; Dell'aquila E; Ratta R; Muda AO; Perrone G; Brunelli C; Correale P; Riva E; Russo A; Loupakis F; Falcone A; Santini D; Tonini G
    Eur J Cancer; 2013 Apr; 49(6):1501-8. PubMed ID: 23266047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
    Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
    Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of miR-135a on HOXA10 expression, proliferation and apoptosis of ovarian cancer cells].
    Tang WW; Wan GP; Wan YC; Zhang L; Cheng WJ
    Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):364-9. PubMed ID: 24016480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
    Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
    Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis].
    Li J; Liang SH; Lu X
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):787-92. PubMed ID: 21176563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
    Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
    Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of serum microRNA-21 in colorectal cancer.
    Menéndez P; Padilla D; Villarejo P; Palomino T; Nieto P; Menéndez JM; Rodríguez-Montes JA
    J Surg Oncol; 2013 Nov; 108(6):369-73. PubMed ID: 23970420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis.
    Gong L; Wang C; Gao Y; Wang J
    Biomed Pharmacother; 2016 Oct; 83():58-63. PubMed ID: 27470550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer.
    Yang Q; Zhang C; Huang B; Li H; Zhang R; Huang Y; Wang J
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):953-7. PubMed ID: 23751352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of microRNA-93 downregulation in human colon cancer.
    Xiao ZG; Deng ZS; Zhang YD; Zhang Y; Huang ZC
    Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):296-301. PubMed ID: 23354160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-150 is a factor of survival in prostate cancer patients.
    Dezhong L; Xiaoyi Z; Xianlian L; Hongyan Z; Guohua Z; Bo S; Shenglei Z; Lian Z
    J BUON; 2015; 20(1):173-9. PubMed ID: 25778313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
    Yang L; Li N; Wang H; Jia X; Wang X; Luo J
    Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
    Hu X; Macdonald DM; Huettner PC; Feng Z; El Naqa IM; Schwarz JK; Mutch DG; Grigsby PW; Powell SN; Wang X
    Gynecol Oncol; 2009 Sep; 114(3):457-64. PubMed ID: 19501389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma.
    Wang Z; Cai H; Lin L; Tang M; Cai H
    Pediatr Blood Cancer; 2014 Feb; 61(2):206-10. PubMed ID: 24038809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer.
    Valladares-Ayerbes M; Blanco M; Haz M; Medina V; Iglesias-Díaz P; Lorenzo-Patiño MJ; Reboredo M; Santamarina I; Figueroa A; Antón-Aparicio LM; Calvo L
    Int J Oncol; 2011 Nov; 39(5):1253-64. PubMed ID: 21743960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.